{"filing":{"accession_number":"0001493152-26-029205","cik":"0001113423","ticker":"CSCIF","company_name":"COSCIENS Biopharma Inc.","form":"6-K","filing_date":"2026-06-18","report_date":null,"primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1113423/000149315226029205/form6-k.htm"},"events":[{"id":12051,"run_id":10611,"accession_number":"0001493152-26-029205","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"Peter H. Puccetti, who has been serving as Interim CEO since November, has been appointed as the Company's permanent full-time President and CEO effective immediately.","company_name":"COSCIENS Biopharma Inc.","ticker":"CSCIF","filing_date":"2026-06-18","form":"6-K","submitted_at":null,"items":[{"id":8791,"accession_number":"0001493152-26-029205","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"Peter H. Puccetti, who has been serving as Interim CEO since November, has been appointed as the Company's permanent full-time President and CEO effective immediately. This is a material executive appointment that would affect investor assessment of leadership continuity and strategic direction. While the exhibit also discloses shareholder meeting results (including director re-elections and auditor re-appointment), the principal announced action is the permanent CEO appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-08fd3440","taxonomy_version":"v1.2","classified_at":"2026-06-21T18:58:36.260937+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":12052,"run_id":10611,"accession_number":"0001493152-26-029205","anchor_item_number":"EX-99.2","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The Company's annual general and special meeting of shareholders held on June 17, 2026 approved three material matters: election of six directors, appointment of Deloitte LLP as auditors, and approval of a special resolution to consolidate and subsequently split the Company's common shares.","company_name":"COSCIENS Biopharma Inc.","ticker":"CSCIF","filing_date":"2026-06-18","form":"6-K","submitted_at":null,"items":[{"id":8792,"accession_number":"0001493152-26-029205","item_number":"EX-99.2","item_title":"ex99-2.htm","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a formal Report of Voting Results submitted pursuant to National Instrument 51-102 Section 11.3, disclosing the outcomes of the Company's annual general and special meeting of shareholders held on June 17, 2026. The report details voting results on three material matters: (1) election of six directors, (2) appointment of Deloitte LLP as auditors, and (3) approval of a special resolution to consolidate and subsequently split the Company's common shares. These shareholder votes, particularly the share capital amendment requiring majority-of-minority approval, are material to investors' assessment of the registrant's governance and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-08fd3440","taxonomy_version":"v1.2","classified_at":"2026-06-21T18:58:36.260937+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8791,"accession_number":"0001493152-26-029205","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"Peter H. Puccetti, who has been serving as Interim CEO since November, has been appointed as the Company's permanent full-time President and CEO effective immediately. This is a material executive appointment that would affect investor assessment of leadership continuity and strategic direction. While the exhibit also discloses shareholder meeting results (including director re-elections and auditor re-appointment), the principal announced action is the permanent CEO appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-08fd3440","taxonomy_version":"v1.2","classified_at":"2026-06-21T18:58:36.260937+00:00","company_name":"COSCIENS Biopharma Inc.","ticker":"CSCIF","filing_date":"2026-06-18"},{"id":8792,"accession_number":"0001493152-26-029205","item_number":"EX-99.2","item_title":"ex99-2.htm","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a formal Report of Voting Results submitted pursuant to National Instrument 51-102 Section 11.3, disclosing the outcomes of the Company's annual general and special meeting of shareholders held on June 17, 2026. The report details voting results on three material matters: (1) election of six directors, (2) appointment of Deloitte LLP as auditors, and (3) approval of a special resolution to consolidate and subsequently split the Company's common shares. These shareholder votes, particularly the share capital amendment requiring majority-of-minority approval, are material to investors' assessment of the registrant's governance and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-08fd3440","taxonomy_version":"v1.2","classified_at":"2026-06-21T18:58:36.260937+00:00","company_name":"COSCIENS Biopharma Inc.","ticker":"CSCIF","filing_date":"2026-06-18"}]}